Loading…
MSD Animal Health has broken ground on a new 1,800 m² production building in Igoville, France, dedicated to manufacturing two external antiparasitics for dogs and cats. The facility will produce 25 million units annually and create 50 jobs, with commercial production starting in 2020.
MSD Animal Health held a groundbreaking ceremony for a new production building at its MMD site in Igoville, France, dedicated to manufacturing Bravecto Spot-on and Bravecto Plus for the global market.
MSD Animal Health announced plans to purchase a manufacturing facility in Krems an der Donau, Austria, currently owned by Shire plc., to expand its global vaccine manufacturing capacity.
| Site | Largest | Latest |
|---|---|---|
| Igoville, France | 2018-10-02 |